Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease.

Objective: Although Remicade (infliximab) is costly relative to non-biologic therapy, its impact on healthcare resource utilization and mucosal healing may make it a cost-effective option. This study aimed to compare gastrointestinal (GI)-related healthcare resource utilization and severity of mucosal damage before and during infliximab therapy in Crohn's disease (CD) or ulcerative colitis (UC) patients.

Methods: A retrospective chart review was conducted at 14 gastroenterology practices from across the country, which varied in practice sizes and types.